Navigation Links
Novartis Pharma Logistics, Inc. voluntarily recalling in Barbados select lots of certain over-the-counter products due to bottle closure defect
Date:2/5/2013

4 oz.

300436345042

67634504

10300436345049

4 oz

10092520

01/31/201310095545

01/31/201310117453

02/28/201310097308

03/31/201310095904

04/30/201310099699

05/31/201310102053

06/30/201310103616

07/31/201310107024

08/31/201310103617

09/30/201310114266

10/31/201310116660

11/30/201310116869

12/31/201310116870

02/28/201410126445

03/31/2014Triaminic®

Daytime/Nighttime Cold

& Cough Club Pack

300436417121

N/A

1030043641713510095327

01/31/201310095907

01/31/201310097748

01/31/201310095298

04/30/201310117817

12/31/201310117818

03/31/201410117819

03/31/2014Triaminic®

Daytime/Nighttime Cold &

Cough Combo Pack

300436216083

67621608

1030043621608010095906

01/31/201310099216

02/28/201310100792

04/30/201310100793

04/30/201310101494

05/31/201310101495

05/31/201310106846

05/31/201310104675

06/30/201310106086

06/30/201310106088

07/31/201310106284

07/31/201310106848

08/31/201310110968

08/31/201310113146

09/30/201310113147

11/30/201310115037

11/30/201310116592

12/31/2013Triaminic® Syrups (Cont.)PRODUCTItem UPC NUMBERNDC NUMBERCase UCC NUMBERSizeLOTEXPIRY DATETriaminic®

Daytime/Nighttime Cold

& Cough Combo Pack

(Cont.)

300436216083

67621608

1030043621608010116595

12/31/201310116596

12/31/201310116599

03/31/201410123383

03/31/201410123388

03/31/2014Triaminic® Dye‐free Long

Acting Cough, 4 oz.

300436350046

67635004

10300436350043

4 oz


'/>"/>
SOURCE Novartis Pharma Logistics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Continued Uptake of Novartis/Incytes Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market
2. Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
3. Thesan Pharmaceuticals offentliggør første runde af venturefinansieringen ledt af Novo Ventures og Novartis Venture Funds i fællesskab
4. Thesan Pharmaceuticals annuncia un finanziamento di serie A co-gestito da Novo Ventures e Novartis Venture Funds
5. Thesan Pharmaceuticals gibt Serie-A-Finanzierung unter gemeinsamer Führung von Novo Ventures und Novartis Venture Funds bekannt
6. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
7. FDA Advisory Committee supports use of tobramycin inhalation powder from Novartis for patients with cystic fibrosis
8. University of Pennsylvania and Novartis Form Alliance to Expand Use of Personalized T Cell Therapy for Cancer Patients
9. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
10. Briefing: Leading Pharma Companies to Watch in Todays Market Session
11. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , March 31, 2015  The efficacy of continuous ... in a recently published study 1 of ultraviolet ... research team, including Curtis Donskey , M.D.  The ... for the same length of time from the same ... unit.  The results showed surprisingly low pathogen kill rates ...
(Date:3/31/2015)... 31, 2015 According to ... Chemical Instrumentation Market (Chromatography, Electrophoresis, DNA Sequencer, PCR, Microplate ... Fume Hood, Centrifuge) - Global Forecast to 2019", ... Chemical Instrumentation Market is expected to reach $48.84 ... 2014 to 2019. Browse   ...
(Date:3/31/2015)... March 31, 2015  Frequentz Inc., a global leader ... white paper to help the pharmaceutical industry understand the ... Chain Security Act (DSCSA). The white paper, "From Lot-based ... GS1 EPCIS Standard(s) and Implementation Plan rollout, ... product tracing requirements that need to occur between now ...
Breaking Medicine Technology:VA Funded Study Validates Continuous UV-C Technology For Pathogen Reduction 2VA Funded Study Validates Continuous UV-C Technology For Pathogen Reduction 3VA Funded Study Validates Continuous UV-C Technology For Pathogen Reduction 4Life Science and Chemical Instrumentation Market Worth $48.84 Billion by 2019 2Life Science and Chemical Instrumentation Market Worth $48.84 Billion by 2019 3Life Science and Chemical Instrumentation Market Worth $48.84 Billion by 2019 4Life Science and Chemical Instrumentation Market Worth $48.84 Billion by 2019 5Frequentz Releases White Paper Addressing DSCSA's Current & Future Impact 2Frequentz Releases White Paper Addressing DSCSA's Current & Future Impact 3
... Nov. 4 Sanford Wittels & Heisler, LLP, along ... a medical device company specializing in cardiac surgical ablation ... Department of Justice (DOJ) in a qui tam case ... a five-year period. , Sanford Wittels & Heisler and ...
... 4 NeoStem, Inc. (NYSE Amex: NBS ), ... named to the Company,s Board of Directors. Dr. ... biotechnology businesses. , Serving as Executive Vice President of ... operations of Abraxis Bioscience, a global biotechnology company dedicated ...
Cached Medicine Technology:Relator's Attorneys Comment On AtriCure/DOJ Proposed Settlement 2NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations 2NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations 3
(Date:3/31/2015)... In conjunction with the Asbestos Awareness ... Mesothelioma Applied Research Foundation (Meso Foundation) announced the ... its existing work in mesothelioma research, education, support, ... Meso Foundation’s mission, we want to eliminate harmful ... asbestos, including mesothelioma,” said the Meso Foundation’s executive ...
(Date:3/31/2015)... Karen A. Daley, Ph.D. will address graduates of ... Commencement ceremony on May 9, 2015 and will receive ... her eminent career as a nurse, public health advocate, ... senior staff nurse at Brigham and Women’s Hospital in ... including President of the American Nurses Association in which ...
(Date:3/31/2015)... Many people, including the ones with physical challenges, ... are only for able-bodied participants. , A new ... to change that thinking. , The program, part ... Sports Expo on Saturday, April 11 (10 a.m. to ... , The event will showcase a wide variety ...
(Date:3/31/2015)... OnChip Devices , a world leader in Integrated ... chip targeted towards low voltage LED applications. Adding to its ... for protecting circuits by suppressing voltage higher than 3.0 Volts. ... up to 350W and 20A, providing protection of 8kV when ... These diodes do not exhibit any device degradation when compared ...
(Date:3/31/2015)... The Walk a Mile Project, as part ... just kicked off their 3rd research sequence. The new ... Substantial Equivalence was and is a massive component of ... at Change The World Films. “We started our research ... even entered our food supply, just to get a bird's ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Research Organization Announces New Prevention Program 2Health News:Mesothelioma Research Organization Announces New Prevention Program 3Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 3Health News:Memorial Healthcare System's Adaptive Sports Expo Encourages Physically Challenged To Go Beyond Perceived Limitations 2Health News:OnChip Introduces Low Voltage Diodes for High-Brightness LED Protection 2Health News:The Walk a Mile Project Launches New Research Sequence on Substantial Equivalence of GMOs 2
... Leading Urology Annual MeetingSUNNYVALE, Calif., April 23 Accuray ... in the field of radiosurgery, announced today that more ... date worldwide using the CyberKnife(R) Robotic Radiosurgery System. In ... approximately 400 prostate cancer patients were treated. The company ...
... LOUIS, April 23 Sigma-Aldrich Corporation, a leading Life Science ... diluted EPS grew by 6% to $0.68 from $0.64 in ... of 2009 were $519 million, a decline of 9% from ... first quarter sales grew organically by 1% from a year ...
... BEACH, Fla., April 23 The Cosmetic Bootcamp LLC announces ... in Aspen, Colorado. Leading skin care experts from dermatology and ... event was made possible by a generous grant from Johnson ... in ethnic skincare. Among the faculty attending this meeting will ...
... PARK, N.J., April 23 OTC Perspectives - a ... company DTC Perspectives Inc. - has announced the finalists ... leading healthcare brands named as finalists are Aleve, Benadryl, ... winners of OTC National Advertising Awards will be announced ...
... Conn., April 23 CuraGen Corporation (Nasdaq: ... first quarter of 2009. During the three month period ... and investments for operations and repurchased $4.8 million of debt ... million of cash and investments. As of March ...
... 23 April: The first identification of GP130 ... today at EASL 2009, the Annual Meeting of ... Disease in Copenhagen, Denmark. , Identification of recurrent ... reveals a new pathway of tumourigenesis in humans, ...
Cached Medicine News:Health News:CyberKnife Radiosurgery Used to Treat More Than 3,000 Prostate Cancer Patients Worldwide 2Health News:CyberKnife Radiosurgery Used to Treat More Than 3,000 Prostate Cancer Patients Worldwide 3Health News:CyberKnife Radiosurgery Used to Treat More Than 3,000 Prostate Cancer Patients Worldwide 4Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 2Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 3Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 4Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 5Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 6Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 7Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 8Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 9Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 10Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 11Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 12Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 13Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 14Health News:Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65. 15Health News:J&J, Schering-Plough, Novartis, Bayer vie for Top Honors at the Premier OTC / Healthcare Ad Awards 2Health News:CuraGen Reports First Quarter 2009 Financial Results 2Health News:CuraGen Reports First Quarter 2009 Financial Results 3Health News:CuraGen Reports First Quarter 2009 Financial Results 4Health News:CuraGen Reports First Quarter 2009 Financial Results 5Health News:New oncogene gives valuable insight into hepatocellular tumors in humans 2
... vascular closure device quickly seals ... procedures, allowing for early ambulation ... creates a mechanical seal by ... bio-absorbable anchor and collagen sponge, ...
Terumo's Optitorque offers superior torque and precision control. It's patient-friendly, high torque design makes it the catheter of choice for demanding angiography....
Jography angiographic catheter has a new material combination, a patented angled weld, a flat wire braid design with a XXL lumen. It also has an atraumatic soft tip....
Femoral selective catheter. Catheter material used is polyurethane (TRICOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Medicine Products: